



US010758550B2

(12) United States Patent
Khairatkar-Joshi et al.**(10) Patent No.: US 10,758,550 B2****(45) Date of Patent: *Sep. 1, 2020****(54) TREATMENT OF ALLERGIC RHINITIS
USING A COMBINATION OF MOMETASONE
AND OLOPATADINE****A61P 27/14** (2018.01); **A61P 37/08** (2018.01);
A61M 11/007 (2014.02); **A61M 15/08**
(2013.01)**(71) Applicant: GLENMARK SPECIALTY S.A., Le**
Chaux-de-Fonds (CH)**(58) Field of Classification Search**CPC **A61K 31/335**; **A61K 31/573**; **A61K 31/58**;
A61K 9/0043; **A61M 11/007**; **A61M**
15/08; **A61P 11/02**; **A61P 27/14**; **A61P**
37/08

See application file for complete search history.

(72) Inventors: Neelima Khairatkar-Joshi, Thane (IN);
Abhay Kulkarni, Navi Mumbai (IN);
Pradeep D. Wale, Maharashtra (IN);
Vikram M. Bhosale, Mumbai (IN);
Piyush Agarwal, Mumbai (IN); **Patrick**
Keohane, London (GB); **Sudeesh K.**
Tantry, Jamison, PA (US); **Chad Oh**,
San Francisco, CA (US)**(56) References Cited**

U.S. PATENT DOCUMENTS

4,871,865 A 10/1989 Lever, Jr. et al.
4,923,892 A 5/1990 Lever, Jr. et al.
5,837,699 A 11/1998 Sequeira et al.
6,127,353 A 10/2000 Yuen et al.
6,841,146 B2 1/2005 Haslwanter et al.
7,977,376 B2 7/2011 Singh et al.
8,399,508 B2 3/2013 Singh et al.
9,078,923 B2 7/2015 Dhuppad et al.
2004/0097474 A1 5/2004 Cagle et al.
2006/0110328 A1 5/2006 Cagle et al.
2008/0058296 A1 3/2008 Chaudry
2012/0121653 A1 5/2012 Jenkins et al.
2015/0099725 A1 4/2015 Khairatkar-Joshi et al.
2015/0250718 A1 9/2015 Dhuppad et al.
2016/0287612 A1 10/2016 Dhuppad et al.**(73) Assignee: GLENMARK SPECIALTY S.A., La**
Chaux-de-Fonds (CH)**(*) Notice:** Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.This patent is subject to a terminal dis-
claimer.**(21) Appl. No.: 15/903,597****(22) Filed: Feb. 23, 2018****(65) Prior Publication Data**

US 2019/0030047 A1 Jan. 31, 2019

Related U.S. Application Data**(63)** Continuation-in-part of application No. 15/842,063,
filed on Dec. 14, 2017, which is a continuation-in-part
of application No. 15/716,661, filed on Sep. 27, 2017,
now abandoned, which is a continuation-in-part of
application No. 15/691,500, filed on Aug. 30, 2017,
now abandoned, which is a continuation-in-part of
application No. 15/636,120, filed on Jun. 28, 2017,
now Pat. No. 10,016,443, which is a
continuation-in-part of application No. 14/682,001,
filed on Apr. 8, 2015, which is a continuation-in-part
of application No. 14/506,122, filed on Oct. 3, 2014.**(30) Foreign Application Priority Data**

Oct. 4, 2013 (IN) 3174/MUM/2013

(51) Int. Cl.**A61K 31/58** (2006.01)
A61K 31/335 (2006.01)
A61P 11/02 (2006.01)
A61P 27/14 (2006.01)
A61K 9/00 (2006.01)
A61P 37/08 (2006.01)
A61K 31/573 (2006.01)
A61M 11/00 (2006.01)
A61M 15/08 (2006.01)**(52) U.S. Cl.**CPC **A61K 31/58** (2013.01); **A61K 9/0043**
(2013.01); **A61K 31/335** (2013.01); **A61K**
31/573 (2013.01); **A61P 11/02** (2018.01);

FOREIGN PATENT DOCUMENTS

EP 2014305 A1 1/2009
WO WO-1995020393 A1 8/1995
WO WO-0126658 A2 4/2001
WO WO-2004043470 A1 5/2004
WO WO-2006057769 A2 6/2006
WO WO-2007026151 A1 3/2007
WO WO-2009003199 A1 12/2008

(Continued)

OTHER PUBLICATIONS

Amrol, et al., Intranasal Steroids for Ocular Symptoms in Allergic
Rhinitis, [http://www.jwatch.org/jw201006100000003/2010/06/10/](http://www.jwatch.org/jw201006100000003/2010/06/10/intranasal-steroids-ocular-symptoms-allergic)
intranasal-steroids-ocular-symptoms-allergic.

Aneeza et al., Allergy Rhinol, 2013, 4:e120-e126.

Anolik R., Allergy Asthma Proc, 2009, 30:406-412.

Anolik R., Int Arch Allergy Immunol, 2008, 147:323-330.

Anolik, et al., Clinical Benefits of Combination Treatment with
Mometasone Furoate Nasal Spray and Loratadine vs Monotherapy
with Mometasone Furoate in the Treatment of Seasonal Allergic
Rhinitis, Ann Allergy Asthma Immunol., 2008, 100:264-271.Austin, et al., Mometasone Furoate is a less specific Glucocorticoid
than Fluticasone Propionate, European Respiratory Journal, 2002,
20:1386-1392.

(Continued)

Primary Examiner — Umamaheswari Ramachandran

(74) Attorney, Agent, or Firm — Blank Rome LLP**(57) ABSTRACT**The present invention relates to a method of treating allergic
rhinitis in a subject (e.g., a pediatric human subject) in need
thereof comprising nasally administering to the subject an
effective amount of a fixed-dose pharmaceutical composi-
tion comprising mometasone or its salt and olopatadine or its
salt.**32 Claims, 3 Drawing Sheets**